Pharmacology, Toxicology and Pharmaceutical Science
Eye Irritation
51%
Broxuridine
51%
Flow Cytometry
37%
Cohort Study
31%
Skin Irritation
29%
Asthma
27%
Prescription Drug
18%
Ulcer Perforation
14%
Monoamine
14%
Toxicological Sciences
14%
Choline Alfoscerate
14%
Statin (Protein)
14%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
14%
C57BL 6 Mouse
14%
Leporidae
14%
Neurotransmitter
14%
Biological Product
14%
Open Angle Glaucoma
14%
Caffeic Acid Phenethyl Ester
14%
Life Expectancy
14%
Diet Induced Obesity
14%
Dermatitis
14%
Retrospective Study
14%
Breast Cancer
14%
Omeprazole
14%
Disease Model
14%
Hospital Pharmacy
14%
Serotonin
14%
Diabetic Macular Edema
14%
Implant
14%
Endothelial Cell Growth Factor
14%
Dexamethasone
14%
Community Pharmacy
14%
Chronic Obstructive Lung Disease
14%
Prevalence
14%
Diazepam
14%
Bronchitis
14%
Acute Otitis Media
14%
Sudden Infant Death Syndrome
14%
Cornea Opacity
11%
Irritant Agent
9%
Enzyme-Linked Immunosorbent Assay
9%
Biosimilar Agent
7%
Long Acting Insulin
7%
Insulin Analog
7%
Cinnamaldehyde
7%
Peptic Ulcer Bleeding
7%
Overall Survival
7%
Rare Disease
7%
Nivolumab
7%
Medicine and Dentistry
Health Care Cost
100%
Biosimilar
29%
Logistic Regression Analysis
22%
Local Lymph Node Assay
22%
Prevalence
21%
Health Outcomes
17%
Base
17%
Diabetes Mellitus
16%
Cross Sectional Study
15%
Sensitization
14%
Breast Cancer
14%
Rebound
14%
Health Care Utilization
14%
Cervical Cancer
14%
Antithrombotic
14%
Atrial Fibrillation
14%
Multiple Chronic Conditions
14%
Long Acting Insulin
14%
Patient Experience
14%
Multiple Myeloma
14%
Non Small Cell Lung Cancer
14%
Meta-Regression
14%
Retrospective Study
14%
Diabetic Macular Edema
14%
Intravitreal Implant
14%
Endothelial Cell Growth Factor
14%
Sex Difference
14%
Prescription Drug
14%
Vitamin K Antagonist
14%
Dexamethasone
14%
Omeprazole
14%
Oropharynx Carcinoma
14%
Hepatitis C
14%
Self-Diagnosis
14%
Gene Linkage
14%
Gene Therapy
14%
Technology Assessment
14%
Treatment Duration
14%
Asthma
12%
Diabetes
10%
Arm
9%
Odds Ratio
8%
Hepatitis C Virus
8%
Proton-Pump Inhibitor
8%
Biological Product
8%
Bone Density
7%
Post-COVID-19
7%
Immunotherapy
7%
Chimeric Antigen Receptor T-Cell Immunotherapy
7%
Nivolumab
7%
Nursing and Health Professions
National Health Insurance
33%
Reproducibility
32%
Health Care Cost
22%
Broxuridine
22%
Local Lymph Node Assay
22%
Flow Cytometry
22%
Independent Practice Association
19%
Prevalence
18%
Quality Adjusted Life Year
18%
Health Status
16%
Health Outcomes
16%
Benzodiazepine Derivative
14%
Ulcer Perforation
14%
Eye Irritation
14%
Open Angle Glaucoma
14%
Health Care Utilization
14%
Treatment Duration
13%
Practice Guideline
11%
Inferential Statistics
10%
Proton Pump Inhibitor
8%
Health Care Personnel
8%
Chimeric Antigen Receptor T-Cell Immunotherapy
7%
Biosimilar Agent
7%
Incremental Cost-Effectiveness Ratio
7%
Adalimumab
7%
Cross-Sectional Study
7%
Gastrointestinal Agent
7%
Drug Use
7%
Adolescent
7%
Patient with Depression
7%
Healthcare System
7%
Odds Ratio
6%
Mortality Rate
6%
Confidence Interval
6%